Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
naltrexone + dronabinol
- Development stage
- Unknown
- Lead developer
- Endo International
- Modality
- Small Molecules
- Administration
- Oral, Injection
01
Overview
A combination of naltrexone, an opioid antagonist used to treat alcohol and opioid dependence, and dronabinol, a synthetic form of delta-9-tetrahydrocannabinol (THC) that acts as a cannabinoid receptor type 1 partial agonist. This combination has been studied for treating opioid dependence, with dronabinol showing efficacy in reducing the severity of opiate withdrawal during acute detoxification when used alongside naltrexone.
02
Targets
CNR1 (Cannabinoid receptor 1)DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on naltrexone + dronabinol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on naltrexone + dronabinol.